Eclosion Ventures manages the Eclosion life science investment fund, which focuses on translating cutting edge science into biotechnology companies developing transformational best-in-diseases therapeutics and platform technologies.
We are builders. Eclosion’s approach is defined by its unique entrepreneurial mindset leading to a strong operational and investment commitment to start-up enterprises. Eclosion is driven by an experienced management team which brings together scientific, operational and financial expertise and a successful track record of company creation, value generation and development of new therapeutics that will transform human healthcare.
We focus on highly innovative science and early stage companies developing new approaches to address high unmet medical needs. Eclosion2 fund’s portfolio companies have developed first-in-class drugs with high potential value to patients in fields such as multiple sclerosis, fibrosis or oncology.
We are enablers. Eclosion private investment fund supports portfolio companies from seed to capital stage up to clinical proof of concept, making significant long term operational and financial commitments to companies that have the potential to change the way patients are treated.
Board of Directors
Novel therapeutic with potential to halt progression in multiple sclerosis
Innovation: First company to develop targeted therapies against Human Endogenous Retrovirus mediated diseases
Novel therpaeutic approach in oncology based on dependence receptors and their impact on cell proliferation
Innovation: First company to develop cancer therapies through targeting dependence receptors
Novel therapeutic approach to treat oxygen radical-mediated pathologies common to most age-related degenerative diseases
Innovation: First company to develop targeted targeted therapies through the effective inhibition of specific NADPH oxidase enzymes
Founding scientists: Spin-off from top Universities: Geneva (CH), Kyoto (J), San Antonio/Texas and Emory/Atlanta (USA).